Anti-Ageing Gene Therapy: Not so Far Away?
Anti-Ageing Gene Therapy: Not so Far Away? Ageing Res Rev. 2019 Oct 26;:100977 Authors: Vaiserman A, De Falco E, Koliada A, Maslova O, Balistreri CR Abstract Improving healthspan is the main objective of anti-ageing research. Currently, innovative gene therapy-based approaches seem to be among the most promising for preventing and treating chronic polygenic pathologies, including age-related ones. The gene-based therapy allows to modulate the genome architecture using both direct (e.g., by gene editing) and indirect (e.g., by viral or non-viral vectors) approaches. Nevertheless, considering the extraordinary complexity of processes involved in ageing and ageing-related diseases, the effectiveness of these therapeutic options is often unsatisfactory and limited by their side-effects. Thus, clinical implementation of such applications is certainly a long-time process that will require many translation phases for addressing challenges. However, after overcoming these issues, their implementation in clinical practice may obviously provide new possibilities in anti-ageing medicine. Here, we review and discuss recent advances in this rapidly developing research field. PMID: 31669577 [PubMed - as supplied by publisher]
Conditions: Diabetic Macular Edema; Diabetic Retinopathy Interventions: Biological: 6E11 vg/eye of ADVM-022; Biological: 2E11 vg/eye of ADVM-022; Biological: Aflibercept Sponsor: Adverum Biotechnologies, Inc. Recruiting
Condition: Hemophilia A Interventions: Drug: Gene therapy; Other: Biological Sponsor: Expression Therapeutics, LLC Not yet recruiting
by David Conesa, Blas Echebarria, Angelina Pe ñaranda, Inmaculada R. Cantalapiedra, Yohannes Shiferaw, Enrique Alvarez-Lacalle Ventricular contraction is roughly proportional to the amount of calcium released from the Sarcoplasmic Reticulum (SR) during systole. While it is rather straightforward to measure calcium levels and contractibility under different physiological conditions, the complexity of calcium handling durin g systole and diastole has made the prediction of its release at steady state impossible. Here we approach the problem analyzing the evolution of intracellular and extracellular calcium fluxes dur...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb June 04, 2020)Read the full story at https://www.prweb.com/releases/catalents_chair_and_ceo_john_chiminski_to_speak_about_r_d_leadership_through_the_pandemic_during_bio_digital/prweb17168666.htm
Publication date: August 2020Source: Biomedicine &Pharmacotherapy, Volume 128Author(s): Hadi Esmaeili Gouvarchin Ghaleh, Masomeh Bolandian, Ruhollah Dorostkar, Ali Jafari, Mahdieh Farzaneh Pour
(Boston Children's Hospital) Using a base editing technique, researchers from Boston Children's Hospital and the Broad Institute, have restored hearing in mice with a known recessive genetic mutation. Researchers repaired one single error in the Tmc1 gene known to cause a hereditary form of deafness. The one-time repair involved switching one incorrect DNA base in the gene with the correct version. This is the first time base editing has been used for a genetic sensory disorder.
Authors: Ghiasi B, Sefidbakht Y, Mozaffari-Jovin S, Gharehcheloo B, Mehrarya M, Khodadadi A, Rezaei M, Ranaei Siadat SO, Uskoković V Abstract The synthetic analogue to biogenic apatite, hydroxyapatite (HA) has a number of physicochemical properties that make it an attractive candidate for diagnosis, treatment of disease and augmentation of biological tissues. Here we describe some of the recent studies on HA, which may provide bases for a number of new medical applications. The content of this review is divided to different medical application modes utilizing HA, including tissue engineering, medical implants, con...
(Seattle Children's) Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb June 02, 2020)Read the full story at https://www.prweb.com/releases/catalent_appoints_charles_lickfold_as_chief_information_officer/prweb17146590.htm
BALA CYNWYD, Pa., June 1, 2020 -- (Healthcare Sales &Marketing Network) -- SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neu... Biopharmaceuticals, Neurology, Personnel SwanBio Therapeutics, adeno-associated virus, adrenomyeloneuropathy